Literature DB >> 17556491

The role of CXCR2 in systemic neovascularization of the mouse lung.

Jesús Sánchez1, Aigul Moldobaeva, Jessica McClintock, John Jenkins, Elizabeth Wagner.   

Abstract

We previously showed increased expression of the ELR+, CXC chemokines in the lung after left pulmonary artery obstruction. These chemokines have been shown in other systems to bind their G protein-coupled receptor, CXCR(2), and promote systemic endothelial cell proliferation, migration, and capillary tube formation. In the present study, we blocked CXCR(2) in vivo using a neutralizing antibody and also studied mice that were homozygous null for CXCR(2). To estimate the extent of neovascularization in this model, we measured systemic blood flow to the left lung 14 days after left pulmonary artery ligation (LPAL). We found blood flow significantly reduced (67% decrease) with neutralizing antibody treatment compared with controls. However, blood flow was not altered in the CXCR(2)-deficient mice compared with wild-type controls after LPAL. To test for ligand availability, we measured macrophage inflammatory protein (MIP)-2 in lung homogenates after LPAL, because this is the predominant CXC chemokine previously shown to be increased after LPAL (22). MIP-2 protein was two- to fourfold higher in the left lung relative to the right lung in all treatment groups 4 h after LPAL and this increase did not differ among groups. We speculate that the CXCR(2)-deficient mice have compensatory mechanisms that mitigate their lack of gene expression and conclude that CXCR(2) contributes to chemokine-induced systemic angiogenesis after pulmonary artery obstruction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556491     DOI: 10.1152/japplphysiol.00037.2007

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  11 in total

Review 1.  The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions.

Authors:  Antonio Citro; Elisa Cantarelli; Lorenzo Piemonti
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

2.  Differential activity of pro-angiogenic CXC chemokines.

Authors:  Aigul Moldobaeva; Amy Baek; Lindsey Eldridge; Elizabeth M Wagner
Journal:  Microvasc Res       Date:  2010-02-06       Impact factor: 3.514

3.  Lung Angiogenesis Requires CD4(+) Forkhead Homeobox Protein-3(+) Regulatory T Cells.

Authors:  Franco R D'Alessio; Qiong Zhong; John Jenkins; Aigul Moldobaeva; Elizabeth M Wagner
Journal:  Am J Respir Cell Mol Biol       Date:  2015-05       Impact factor: 6.914

4.  Increased hyaluronan fragmentation during pulmonary ischemia.

Authors:  Lindsey Eldridge; Aigul Moldobaeva; Elizabeth M Wagner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-05       Impact factor: 5.464

5.  Effects of ischemia on lung macrophages.

Authors:  Aigul Moldobaeva; Nico van Rooijen; Elizabeth M Wagner
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

6.  Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer.

Authors:  Miao-Qun Xue; Jun Liu; Jian-Feng Sang; Lei Su; Yong-Zhong Yao
Journal:  Oncotarget       Date:  2017-07-25

Review 7.  Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.

Authors:  Helen Ha; Bikash Debnath; Nouri Neamati
Journal:  Theranostics       Date:  2017-04-07       Impact factor: 11.556

8.  Strain variation in response to lung ischemia: role of MMP-12.

Authors:  Clarke G Tankersley; Aigul Moldobaeva; Elizabeth M Wagner
Journal:  Respir Res       Date:  2012-10-12

9.  Chemokine localization in bronchial angiogenesis.

Authors:  Maria Grazia Perino; Aigul Moldobaeva; John Jenkins; Elizabeth M Wagner
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

10.  Rationale and Means to Target Pro-Inflammatory Interleukin-8 (CXCL8) Signaling in Cancer.

Authors:  Laura M Campbell; Pamela J Maxwell; David J J Waugh
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.